SOUTH SAN FRANCISCO, Calif. / Apr 03, 2025 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9,... Read More

Phase 3 NEAT clinical trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomization Existing cash position of $40.8 million expected to provide operating runway through Phase 3 topline results into 2026 SOUTH SAN FRANCISCO, Calif. / Mar 24, 2025 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of... Read More

Phase 3 NEAT clinical trial nearing 50% enrollment; company reiterates expectation of enrollment completion in second quarter of 2025 and topline results in fourth quarter of 2025 SOUTH SAN FRANCISCO, Calif. / Feb 07, 2025 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced that... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 05, 2025 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Oppenheimer 35 th Annual Healthcare Life Sciences... Read More

Allowance to extend into 2036 patent claims related to method of treating patients with A-T using the company’s proprietary EryDex process SOUTH SAN FRANCISCO, Calif. / Feb 04, 2025 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced that the U.S. Patent and Trademark Office... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 28, 2025 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that it will host an investor webinar focused on addressing the high unmet need in the company’s lead rare pediatric neurodegenerative disease indication, Ataxia-Telangiectasia... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 27, 2025 / Business Wire / Quince Therapeutics, Inc . (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the online publication of safety data from patients with Ataxia-Telangiectasia (A-T) treated with EryDex for a minimum of 24 months in Frontiers in Neurology . “A-T is a rare... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 23, 2025 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric... Read More

Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients SOUTH SAN FRANCISCO, Calif. / Nov 13, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s development... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 12, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from its prior Phase 3 ATTeST ( A taxia- T elangiectasia T rial with the E... Read More

SOUTH SAN FRANCISCO, Calif. / Nov 11, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation at the 53 rd Child Neurology Society (CNS) Annual Meeting of safety data from its prior Phase 3 ATTeST ( A taxia- T elangiectasia T rial with the E ryDex... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 14, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences: 2024 Maxim Healthcare Virtual Summit – Quince’s Chief Executive Officer and Chief Medical Officer Dirk Thye,... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 03, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the H.C. Wainwright 26 th Annual Global Investment Conference on September 9,... Read More

Findings from largest completed study in A-T demonstrated favorable safety profile Study showed positive effect of EryDex treatment in a subset of patients with A-T ages six to nine – the age range that typically experiences rapid clinical decline Quince recently initiated pivotal Phase 3 NEAT study, which is currently enrolling and being conducted under U.S. FDA Special Protocol Assessment agreement SOUTH SAN FRANCISCO,... Read More

Strong cash position expected to provide sufficient operating runway into 2026; Phase 3 topline results expected in the fourth quarter of 2025 SOUTH SAN FRANCISCO, Calif. / Aug 13, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today provided an update on the company’s... Read More

SOUTH SAN FRANCISCO, Calif. / Jun 25, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that the first patient has been dosed in the company’s Phase 3 NEAT ( N eurologic E ffects of EryDex on Subjects with A - T ) clinical trial... Read More

Fast Track designation underscores the high unmet medical need, with currently no approved therapeutic treatments for the rare pediatric disease Ataxia-Telangiectasia SOUTH SAN FRANCISCO, Calif. / Jun 03, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease... Read More

SOUTH SAN FRANCISCO, Calif. / May 13, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the first quarter ended March 31, 2024. Dirk Thye, M.D.,... Read More

SOUTH SAN FRANCISCO, Calif. / May 06, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at The Citizens JMP Life Sciences Conference... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 01, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient’s own biology to deliver rare disease therapeutics, today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.... Read More

World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company’s lead Phase 3 asset, new indications, and pipeline expansion SOUTH SAN FRANCISCO, Calif. / Feb 22, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 15, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company’s Board of Directors. “We... Read More

SOUTH SAN FRANCISCO, Calif. / Feb 07, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Oppenheimer 34 th Annual Healthcare Life... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 04, 2024 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at two investor events taking place in San... Read More

SOUTH SAN FRANCISCO, Calif. / Oct 23, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company. Quince’s newly acquired Phase 3 lead asset,... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 28, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that the U.S. Food and Drug Administration (FDA or the “Agency”) has lifted the partial clinical hold on EryDel S.p.A’s Investigational New Drug (IND) application for its lead... Read More

SOUTH SAN FRANCISCO, Calif. / Sep 06, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company’s corporate legal activities and intellectual... Read More

SOUTH SAN FRANCISCO, Calif. / Aug 10, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, announced that Dirk Thye, M.D., the company’s Chief Executive Officer, will present at the Sidoti Virtual Investor Conference on Thursday, August 17, 2023, at 3:15 p.m. Eastern Time (12:15... Read More

Well-capitalized into 2026 with ability to fully fund lead asset EryDex expected through Phase 3 trial under special protocol assessment (SPA) and to NDA submission EryDex utilizes autologous intracellular drug encapsulation (AIDE) technology designed for slow release of steroids over several weeks without long-term toxicity typically associated with chronic administration Potential for rapid expansion of EryDex to other... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 11, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors unanimously rejected the unsolicited proposal it received from Echo Lake Capital to acquire Quince for $1.60 per share in cash. Following careful... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 06, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that it has retained MTS Health Partners, L.P. (MTS) as its financial advisor to support Quince’s Board of Directors and management team in the review and evaluation of... Read More

SOUTH SAN FRANCISCO, Calif. / Apr 05, 2023 / Business Wire / Q uince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced that its Board of Directors (the “Board”) unanimously approved the adoption of a limited duration stockholder rights plan (the “Rights Plan”) and declared a dividend... Read More

SOUTH SAN FRANCISCO, Calif. / Mar 22, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today confirmed that it received an unsolicited offer to acquire the company from Echo Lake Capital. Quince’s Board of Directors, consistent with its fiduciary responsibilities, will... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 30, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today provided an update on the company’s development pipeline and business outlook for 2023. The company intends to prioritize capital resources toward the expansion of its development... Read More

SOUTH SAN FRANCISCO, Calif. / Jan 27, 2023 / Business Wire / Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced the sale of the company’s legacy small molecule protease inhibitor portfolio, including COR588, COR388, COR852, and COR803, pursuant to an asset purchase agreement with Lighthouse Pharmaceuticals,... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at the Military Health System Research Symposium (MHSRS 2022), which took place September 12 to September 15, 2022, in Kissimmee, Florida. At MHSRS 2022, Quince presented a poster showcasing the broad... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), which took place September 9 to September 12, 2022, in Austin, Texas. At ASBMR 2022, Quince presented two posters showcasing the... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today presented preclinical data at the 14 th International Conference on Osteogenesis Imperfecta (OI 2022) demonstrating the potential of its novel targeted therapeutic NOV004 to treat fracture in osteogenesis imperfecta (OI) by promoting accelerated increases in bone... Read More

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a number of scientific meetings taking place in September 2022, including the 14 th International Conference on Osteogenesis Imperfecta (OI 2022), The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022),... Read More